Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Probable serine protease inhibitor.. Additionally we are shipping Serine Peptidase Inhibitor, Kazal Type 7 (Putative) Kits (7) and Serine Peptidase Inhibitor, Kazal Type 7 (Putative) Proteins (6) and many more products for this protein.
Showing 10 out of 38 products:
Human Polyclonal SPINK7 Primary Antibody for EIA, IHC (p) - ABIN1450063
Cui, Wang, Zhang, Lang, Bi, Guo, Lu: ECRG2, a novel candidate of tumor suppressor gene in the esophageal carcinoma, interacts directly with metallothionein 2A and links to apoptosis. in Biochemical and biophysical research communications 2003
miR (show MLXIP Antibodies)-1322 can regulate ECRG2 in an allele-specific manner and that serum levels of miR (show MLXIP Antibodies)-1322 can serve as a potential diagnostic biomarker for patients with ESCC.
Conformational study of ECRG2 using NMR.
ECRG2 is a novel member of the Kazal-type serine protease inhibitor family and may function as a tumor suppressor gene regulating the protease cascades during carcinogenesis and invasion of esophageal cancer.
ECRG2 regulates invasion/migration partly through ECM (show MMRN1 Antibodies) degradation and uPA (show PRAP1 Antibodies)/uPAR (show PLAUR Antibodies)/FPRL1 (show FPR2 Antibodies) pathway
Data suggest that the physical interaction of esophageal cancer related gene 2 (ECRG2) and metallothionein 2A (MT2A (show MT2 Antibodies)) may play an important role in the carcinogenesis of esophageal cancer.
Potential interaction partner for ECRG2 might be involved in regulation of cell proliferation and apoptosis and in various physiological processes.
Short tandem repeat polymorphism in a novel esophageal cancer-related gene (ECRG2) implicates susceptibility to esophageal cancer
Short tandem repeat polymorphism TCA3/TCA3 (show CCL1 Antibodies) in exon 4 of ECRG2 is associated with poor relapse-free survival in surgically completely resected oral squamous cell carcinoma patients and might be a potential prognostic marker
results suggest that ECRG2 inhibits aggressiveness of cancer cell, possibly through the down-regulation of uPA (show PRAP1 Antibodies)/plasmin (show PLG Antibodies) activity
genetically fixed short tandem repeat polymorphism TCA3/TCA3 (show CCL1 Antibodies) in exon 4 of ECRG2 is associated with poor clinical outcome in surgically treated esophageal cancer patients and might be a potential prognostic marker
Probable serine protease inhibitor.
, esophagus cancer-related gene 2 protein
, esophagus cancer-related protein 2
, serine peptidase inhibitor, Kazal type 7 (putative)
, serine protease inhibitor Kazal-type 7
, allergen Gal d 1
, allergen Gal d I
, esophagus cancer related gene 2
, esophagus cancer-related gene-2